143 related articles for article (PubMed ID: 38243419)
1. Imageable Biomarkers for Radiotherapy Response.
Woliner-van der Weg W; Span PN; Braam PM; Bussink J
Prog Tumor Res; 2017; 44():11-24. PubMed ID: 38243419
[TBL] [Abstract][Full Text] [Related]
2.
Qian Y; Von Eyben R; Liu Y; Chin FT; Miao Z; Apte S; Carter JN; Binkley MS; Pollom EL; Harris JP; Prionas ND; Kissel M; Simmons A; Diehn M; Shultz DB; Brown JM; Maxim PG; Koong AC; Graves EE; Loo BW
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1183-1192. PubMed ID: 29859786
[TBL] [Abstract][Full Text] [Related]
3. Developing Predictive or Prognostic Biomarkers for Charged Particle Radiotherapy.
Story MD; Wang J
Int J Part Ther; 2018; 5(1):94-102. PubMed ID: 30393751
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia imaging with
Melsens E; De Vlieghere E; Descamps B; Vanhove C; Kersemans K; De Vos F; Goethals I; Brans B; De Wever O; Ceelen W; Pattyn P
Radiat Oncol; 2018 Mar; 13(1):39. PubMed ID: 29514673
[TBL] [Abstract][Full Text] [Related]
5. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.
Franklin J; Eichenauer DA; Becker I; Monsef I; Engert A
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD008814. PubMed ID: 28901021
[TBL] [Abstract][Full Text] [Related]
6. Predictive modeling of hypoxic head and neck cancers during fractionated radiotherapy with gold nanoparticle radiosensitization.
Huynh M; Kempson I; Bezak E; Phillips W
Med Phys; 2021 Jun; 48(6):3120-3133. PubMed ID: 33818799
[TBL] [Abstract][Full Text] [Related]
7. Clinically relevant biomarkers in targeted radiotherapy.
Stea B; Gordon J
Clin Exp Metastasis; 2012 Oct; 29(7):853-60. PubMed ID: 22886523
[TBL] [Abstract][Full Text] [Related]
8. A systematic overview of radiation therapy effects in head and neck cancer.
Zackrisson B; Mercke C; Strander H; Wennerberg J; Cavallin-Ståhl E
Acta Oncol; 2003; 42(5-6):443-61. PubMed ID: 14596506
[TBL] [Abstract][Full Text] [Related]
9. Hypoxic tumour cell-derived exosomal miR-340-5p promotes radioresistance of oesophageal squamous cell carcinoma via KLF10.
Chen F; Xu B; Li J; Yang X; Gu J; Yao X; Sun X
J Exp Clin Cancer Res; 2021 Jan; 40(1):38. PubMed ID: 33485367
[TBL] [Abstract][Full Text] [Related]
10. Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors.
Eckert F; Zwirner K; Boeke S; Thorwarth D; Zips D; Huber SM
Front Immunol; 2019; 10():407. PubMed ID: 30930892
[TBL] [Abstract][Full Text] [Related]
11. Radiation-responsive scintillating nanotheranostics for reduced hypoxic radioresistance under ROS/NO-mediated tumor microenvironment regulation.
Dou Y; Liu Y; Zhao F; Guo Y; Li X; Wu M; Chang J; Yu C
Theranostics; 2018; 8(21):5870-5889. PubMed ID: 30613268
[TBL] [Abstract][Full Text] [Related]
12. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers.
Bussink J; Kaanders JH; van der Kogel AJ
Radiother Oncol; 2003 Apr; 67(1):3-15. PubMed ID: 12758235
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Supramolecular Radiosensitizer Based on Hypoxia-Responsive Macrocycle.
Hou X; Chang YX; Yue YX; Wang ZH; Ding F; Li ZH; Li HB; Xu Y; Kong X; Huang F; Guo DS; Liu J
Adv Sci (Weinh); 2022 Feb; 9(6):e2104349. PubMed ID: 34994113
[TBL] [Abstract][Full Text] [Related]
15. Hadrontherapy Interactions in Molecular and Cellular Biology.
Thariat J; Valable S; Laurent C; Haghdoost S; Pérès EA; Bernaudin M; Sichel F; Lesueur P; Césaire M; Petit E; Ferré AE; Saintigny Y; Skog S; Tudor M; Gérard M; Thureau S; Habrand JL; Balosso J; Chevalier F
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31878191
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer.
Koukourakis MI
Semin Oncol; 2002 Dec; 29(6 Suppl 19):42-6. PubMed ID: 12577243
[TBL] [Abstract][Full Text] [Related]
17. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
18. The relevance of molecular biomarkers in cervical cancer patients treated with radiotherapy.
Kilic S; Cracchiolo B; Gabel M; Haffty B; Mahmoud O
Ann Transl Med; 2015 Oct; 3(18):261. PubMed ID: 26605307
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
Reboul FL
Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280
[TBL] [Abstract][Full Text] [Related]
20. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.
Bourhis J; Sire C; Graff P; Grégoire V; Maingon P; Calais G; Gery B; Martin L; Alfonsi M; Desprez P; Pignon T; Bardet E; Rives M; Geoffrois L; Daly-Schveitzer N; Sen S; Tuchais C; Dupuis O; Guerif S; Lapeyre M; Favrel V; Hamoir M; Lusinchi A; Temam S; Pinna A; Tao YG; Blanchard P; Aupérin A
Lancet Oncol; 2012 Feb; 13(2):145-53. PubMed ID: 22261362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
